Pfizer and Bristol Myers Squibb to Offer Eliquis via Mark Cuban Cost Plus Drug Company

What happened

Pfizer and Bristol Myers Squibb announced that Eliquis (apixaban) will be made available through Mark Cuban Cost Plus Drug Company, a platform known for transparent, low-cost pricing. This move reflects a strategy to secure volume and patient access amid increasing payer and policy pressure, but it likely comes at the expense of net price. For Pfizer, Eliquis is a critical revenue contributor, and this distribution channel could accelerate the erosion of pricing power before the product faces generic competition. The decision aligns with Pfizer's broader cost-control narrative but introduces a new variable that could pressure the revenue outlook toward the lower end of 2026 guidance. Investors should monitor whether this marks a broader shift in Pfizer's commercial strategy or remains a tactical concession.

Implication

The move signals a willingness to accept lower margins to sustain volume, potentially setting a precedent for other products and accelerating the decline in pricing power across Pfizer's portfolio. This increases reliance on cost savings and pipeline success to offset revenue erosion, raising the risk to the base-case scenario.

Thesis delta

The Eliquis Cost Plus deal introduces a new channel that likely reduces net pricing, potentially undermining the revenue stability assumed in the base case. While it may secure volume, it signals a willingness to accept lower prices earlier than expected, increasing downside risk to 2026 revenue and earnings estimates. This development shifts the thesis toward a more cautious stance, as pricing power erosion becomes a more tangible risk.